Reversal of Severe Volume Deplete Acute Kidney Injury by Rasburicase

Edward P. Nord, Deep Patel, Heesuck Suh, Nand K. Wadhwa

Division of Nephrology, Department of Medicine, School of Medicine, State University of New York at Stony Brook, Stony Brook, USA.

DOI: 10.4236/ojneph.2012.24014                

Abstract

We report on a case of acute kidney injury in a patient with severe volume depletion from high ileostomy output and poor oral intake associated with hyperuricemia and hyperkalemia. The patient presented with similar features on three separate admissions. A conservative management approach was undertaken that included infusion of rasburicase, since the patient refused to undergo hemodialysis on each occasion. Rasburicase is a recombinant urate oxidase enzyme that converts uric acid to allantoin which is five to ten times more soluble than uric acid in urine, thereby enhancing urinary excretion. Rasburicase was administered each time and was followed by a prompt increase in urine output, rapid decrease in serum uric acid level, and recovery of renal function without the need for acute renal replacement therapy. We believe that rasburicase, with a molecular weight of 34 kDa, crossed the glomerular filtration barrier and entered the tubular fluid where it dissolved intra-tubular uric acid, thus relieving obstruction, thereby rapidly enhancing urine excretion and improving renal function. Based on this experience, we propose that rasburicase offers an alternative treatment for acute kidney injury in similar types of settings. To the best of our knowledge this is the first reported case in this situation.

Keywords

Acute Kidney Injury; Rasburicase; Hyperuricemia; Ileostomy

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	W. J. Weise, et al., “Acute Electrolyte and Acid-Base Disorders in Patients with Ileostomies: A Case Series,” American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation, Vol. 52, No. 3, 2008, pp. 494-500.
[2]	L. Cammalleri and M. Malaguarnera, “Rasburicase Represents a New Tool for Hyperuricemia in Tumor Lysis Syndrome and in Gout,” International Journal of Medical Sciences, Vol. 4, No. 2, 2007, pp. 83-93. doi:10.7150/ijms.4.83
[3]	S. C. Howard, D. P. Jones and C. H. Pui, “The Tumor Lysis Syndrome,” The New England Journal of Medicine, Vol. 364, No. 19, 2011, pp. 1844-1854. doi:10.1056/NEJMra0904569
[4]	R. W. Chesney, et al., “Acute Renal Failure: An Important Complication of Cardiac Surgery in Infants,” The Journal of Pediatrics, Vol. 87, No. 3, 1975, pp. 381-388. doi:10.1016/S0022-3476(75)80640-8
[5]	A. A. Ejaz, et al., “Uric Acid: A Novel Risk Factor for Acute Kidney Injury in High-Risk Cardiac Surgery Patients?” American Journal of Nephrology, Vol. 30, No. 5, 2009, pp. 425-429. doi:10.1159/000238824
[6]	A. A. Ejaz, et al., “Effect of Uric Acid Lowering Therapy on the Prevention of Acute Kidney Injury in Cardiovascular Surgery,” International Urology and Nephrology, 2012. doi:10.1007/s11255-012-0192-2
[7]	A. A. Ejaz, et al., “Could Uric Acid Have a Role in Acute Renal Failure?” Clinical Journal of the American Society of Nephrology, Vol. 2, No. 1, 2007, pp. 16-21. doi:10.2215/CJN.00350106
[8]	J. D. Conger, et al., “A Micropuncture Study of the Early Phase of Acute Urate Nephropathy,” The Journal of Clinical Investigation, Vol. 58, No. 3, 1976, pp. 681-689. doi:10.1172/JCI108514
[9]	L. G. Sanchez-Lozada, et al., “Mild Hyperuricemia Induces Glomerular Hypertension in Normal Rats,” American Journal of Physiology. Renal Physiology, Vol. 283, No. 5, 2002, pp. F1105-F1110.
[10]	U. M. Khosla, et al., “Hyperuricemia Induces Endothelial Dysfunction,” Kidney International, Vol. 67, No. 5, 2005, pp. 1739-1742. doi:10.1111/j.1523-1755.2005.00273.x
[11]	J. Kanellis, et al., “Uric Acid Stimulates Monocyte Chemo Attractant Protein-1 Production in Vascular Smooth Muscle Cells via Mitogen-Activated Protein Kinase and Cyclooxygenase-2,” Hypertension, Vol. 41, No. 6, 2003, pp. 1287-1293. doi:10.1161/01.HYP.0000072820.07472.3B
[12]	A. M. Clarke, et al., “Chronic Dehydration and Sodium Depletion in Patients with Established Ileostomies,” Lancet, Vol. 2, No. 7519, 1967, pp. 740-743. doi:10.1016/S0140-6736(67)91945-9
[13]	R. Adler, et al., “Hyperuricemia in Diarrheal Dehydration,” American Journal of Diseases of Children, Vol. 136, No. 3, 1982, pp. 211-213.
[14]	T. P. Segura, et al., “Efficacy of Rasburicase Therapy in Obstructive Renal Failure Secondary to Urolithiasis: A Novel Therapeutic Option,” Nefrologia: Publicacionoficial de la Sociedad Espanola Nefrologia, Vol. 28, No. 1, 2008, pp. 102-105.
[15]	A. A. Acosta and R. J. Hogg, “Rasburicase for Hyperuricemia in Hemolytic Uremic Syndrome,” Pediatric Nephrology, Vol. 27, No. 2, 2012, pp. 325-329.
[16]	P. Y. Lin, et al., “Rasburicase Improves Hyperuricemia in Patients with Acute Kidney Injury Secondary to Rhabdomyolysis Caused by Ecstasy Intoxication and Exertional Heat Stroke,” Pediatric Critical Care Medicine, Vol. 12, No. 6, 2011, pp. e424-e427.
[17]	J. D. Conger and S. A. Falk, “Intrarenal Dynamics in the Pathogenesis and Prevention of Acute Urate Nephropathy,” The Journal of Clinical Investigation, Vol. 59, No. 5, 1977, pp. 786-793. doi:10.1172/JCI108700